Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Introduction: Troponins and brain natriuretic peptide are specific biomarkers linked to myocardial injury and heart failure. Biomarkers blood levels are inversely related to glomerular filtration rate. Previous publications have assessed their predictive role to mortality in renal failure patients. Discussion: Age and troponin blood levels seemed to be useful indicators to predict mortality in our chronic renal failure patients. Materials and Methods: Prospective study that followed 98 patients with chronic kidney disease on dialysis treatment during four years. The main goal was establishing blood levels of both biomarkers in renal failure. Patients with a past history of ischemic heart disease and heart failure were excluded. Bivariate, multivariate analysis and ROC curves were applied. A p-value <0.05 was accepted as significant. Results: Patients´mean age was 50.7 ± 27.2 yearsold; range 20-87 y.o. Mean serum troponins I (TnI-us) blood level was 59 ± 64,9 ng/mL and brain natriuretic peptide 507.3 ± 633.3 pg/mL. In the logistic regression model, troponin and age were significant predictors of mortality (p <0.01). ROC curves let us to obtain cutoff biomarker levels.
Arango SS. Biomarcadores para la evaluación de riesgo en la salud humana. Rev. Fac. Nac. Salud Pública 2011; 30(1): 75-82
Le EH, Klootwijk PJ, Weimar W et al. Significance of acute versus chronic troponin T elevation in dialysis patients. Nephron Clin Pract 2004; 98: c87–c9
Luciardi, H. (2012). Rol creciente de las troponinas cardíacas como multimarcadores. Revista de La Federación Argentina de Cardiología, 41(3), 149–150
Katrukha, I. A. (2013). Human Cardiac Troponin Complex. Structure and Functions, Biochemistry (Moscow), 78(13), 1447–1465
Reed G. W, Rossi J. E, & Cannon C. P. (2017, January 14). Acute myocardial infarction. The Lancet. Lancet Publishing Group. https://doi.org/10.1016/S0140-6736(16)30677-8
Thygesen K, Alpert J. S, Jaffe A. S., Simoons M. L, Chaitman B. R, White, H. D, Wagner, D. R. (2012). Third universal definition of myocardial infarction. European Heart Journal, 33(20), 2551–2567. https://doi.org/10.1093/eurheartj/ehs184
Goldstein S. L. (2011). Acute kidney injury biomarkers : renal angina and the need for a renal troponin I. BMC Medicine 2011, 9:135
Jacobs L. H, Kerkhof J. J. Van De, et al. Inflammation, overhydration and cardiac biomarkers in aemodialysis patients : a longitudinal study, Nephrol Dial Transplant (2010) 25: 243–248
DeFilippi C, Wasserman S, Rosanio S et al. Cardiac troponin T and C-reactive protein for predicting rognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353–359
Sommerer C, Giannitsis E, Schwenger V et al. Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro- B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract 2007; 107: c77–c81
Macin S. M, Reyes L, Lange J, Perna E. R, Coronel M. L, Brizuela, M.,… Arjol, B. G. (2016). Valor pronóstico del NT-proBNP en pacientes con infarto agudo de miocardio con elevación del segmento ST. Revista de La Federación Argentina de Cardiología, 45(3), 130–134
Wu AH, Apple FS, GilberWB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. 1999 Jun; 45(7): 1104-21
Panteghini M, Gerhardt W, Apple FS, et al. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001; 39:174-8
Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P, Alexander P, Poole-Wilson Strömberg A, Veldhuisen D, Dan Atar ... ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. European Heart Journal, Volume 29, Issue 19, 1 October 2008, Pages 2388–2442
Apple, F. S. (2004). Multi-Biomarker Risk Stratification of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C - reactive protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-Cause Death. Clinical Chemistry, 50(12), 2279–2285. http://doi.org/10.1373/clinchem.2004.035741
Arici M, & Walls J. (2001). End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney International, 59(2), 407–414. http://doi.org/10.1046/j.1523-1755.2001.059002407.x
Zimmermann J, Herrlinger S, Pruy A, Metzger T, & Wanner, C. (1999). Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney International, 55(2), 648–658. http://doi.org/10.1046/j.1523-1755.1999.00273.x
Mehta R. L, Kellum J. A, Shah S V, Molitoris B. A, Ronco C, Warnock D. G, & Levin A. (2007). Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care, 11(2), R31. http://doi.org/10.1186/cc5713-
Mongeon F, Effect of Hemodialysis, Coronary Artery Disease and Diabetes on Cardiac Troponin T: A Prospective Survey Over One Year, The Open Cardiovascular Medicine Journal, 2009, 3, 69-77
Serrano Ríos M. Factores de riesgo cardiovascular en el paciente diabético, En: Recomendaciones diagnósticas y terapéuticas, Edición 2004, SEMI, Sociedad Española de Medicina Interna
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.